Capricor Therapeutics, Inc. Stock 12‑Month Price Target Raised to $27, Implies 228% Upside

CAPR Stock Rises As Clinical Trial Investigators Write To FDA Urging Approval For Deramiocel

Capricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10

At 4:30 p.m. ET on Nov. 10, Capricor will host a results call.

FDA Decision Watch: Regeneron And Roche’s Autoimmune Drugs, Capricor’s DMD Therapy In Spotlight

Why Inovio Pharmaceuticals Shares Are Trading Higher By Over 230%; Here Are 20 Stocks Moving Premarket

CAPR Stock Rallies Into FDA Decision Month: Retail Spots Approval ‘Tea Leaves’ In Capricor’s Launch Team Hiring

Postmarket Movers: After-Hours Gainers and Losers

12 Health Care Stocks Moving In Friday's After-Market Session

CAPR Stock on Track For Worst Month Since July AdCom Vote On Deramiocel As November FDA Decision Nears

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy - Slideshow

CAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA Decision

Capricor Highlights Two-Year Deramiocel Data as FDA Decision Nears

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript

Capricor’s DMD Therapy Shows 76% Slower Upper-Limb Decline — This Analyst Expects A Complete Response Letter In November